

CSD/BM/SE/2025-2026

January 29, 2026

**To**  
**Department of Corporate Services**  
**BSE Limited**  
**25th Floor, P. J. Towers,**  
**Dalal Street, Mumbai - 400 001**

**To**  
**Listing Department**  
**National Stock Exchange of India Limited**  
**Exchange Plaza, Bandra Kurla Complex**  
**Bandra (E), Mumbai – 400 051**

**Scrip Code: 530239****Scrip Symbol: SUVEN**

Dear Sir/Madam,

**Sub: Outcome of the Meeting of Board of Directors of Suven Life Sciences Limited held on Thursday, January 29, 2026**

.....

Pursuant to the provisions of Regulation 30 of the SEBI (LODR) Regulations, 2015, as amended and other applicable provisions of law, we wish to inform you that the Board of Directors of the company, at its meeting held today i.e. January 29, 2026, has *inter-alia* considered and approved the following along with other business matters.

**1. Approved the Un-audited Standalone and Consolidated Financial Results**

Took on record and approved the attached Un-audited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended **December 31, 2025** pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 along with Limited Review Reports of the Statutory Auditors.

**2. Allotment of 44,77,612 Equity Shares of the Company on preferential basis upon conversion 44,77,612 fully paid warrants**

The Board of Directors has approved the conversion of 44,77,612 fully paid warrants and issued & allotted 44,77,612 (Forty-four lakhs seventy-seven thousand six hundred and twelve) Equity Shares of Rs.1/- each to the following Non-Promoter Persons/ Entities at an issue price of Rs. 134/- per share on preferential basis in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.

<b>Sl. No.</b>	<b>Non-promoter persons/entities</b>	<b>No. of Equity shares allotted</b>
1.	3P INDIA EQUITY FUND 1	33,58,209
2.	3P INDIA EQUITY FUND 1M	11,19,403
	<b>Total</b>	<b>44,77,612</b>

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suvenc.com website: www.suven.com

Further we would like to inform that the Company has received from above said allottees 100% consideration amount aggregating to Rs. 60,00,00,008/- in compliance with SEBI (ICDR) Regulations, 2018.

**Consequently, the paid-up equity share capital of the company stands increased to the following:**

<b>Particulars</b>	<b>No. of Equity Shares</b>	<b>Amount in INR</b>
Pre-issue subscribed & paid-up capital	22,74,74,207	22,74,74,207.00
<b>Post-issue subscribed &amp; paid-up capital</b>	<b>23,19,51,819</b>	<b>23,19,51,819 .00</b>

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure A**.

**3. Resignation of Mr. Shrenik Soni, Company Secretary & Compliance Officer (KMP) of the Company**

Board of Directors in its meeting held today took note of resignation tendered by Mr. Shrenik Soni (ICSI M. No.: F12400), Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company, to pursue an alternate career opportunity and there is no other material reason. The resignation was accepted by the Board and recorded appreciation for the services rendered by Mr. Shrenik Soni during his tenure. Board then approved to relive him from his duties and all statutory/designated positions with effect from close of business hours on January 30, 2026. Copy of the resignation letter is enclosed with this letter.

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure B**.

**4. Appointment of Ms. Sangeetha Laxmi Kandari (ICSI M. No. A40736) as Company Secretary & Compliance Officer of the Company (Key Managerial Personnel)**

We wish to inform you that the Board of Directors at its meeting held today i.e. January 29, 2026, based on the recommendations of Nomination and Remuneration Committee held on January 29, 2026, considered and approved the appointment of Ms. Sangeetha Laxmi Kandari (ICSI M. No. A40736) as Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company with effect from February 02, 2026.

**Suven Life Sciences Limited**

Ms. Sangeetha Laxmi will also act as Compliance Officer of the Company as required SEBI (LODR) Regulations and SEBI (PIT) Regulations, 2015.

In view of the above and pursuant to Regulation 30(5) of the SEBI LODR Regulations the contact details of Ms. Sangeetha Laxmi Kandari, authorized as KMP under the Company's Policy on criteria for determining the materiality for disclosure of events or information with effect from February 02, 2026, are as follows:

Suven Life Sciences Limited; Address: 8-2-334, SDE Serene Chambers, 6th Floor, Road No.5, Avenue 7, Banjara Hills, Hyderabad – 500034, Telangana.  
Tel. 040-2354 1142/1152; Email: sangeethak@suven.com

Disclosure required pursuant to Regulation 30 and Schedule III of the SEBI (LODR) Regulations, 2015 read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is enclosed herewith as **Annexure C**.

Further, we are enclosing herewith the following documents:

- a) Unaudited Standalone and Consolidated Financial Results for the quarter & nine months ended December 31, 2025
- b) Limited Review Reports of Statutory Auditors of the Company on the Financial Results and
- c) Press Release

Update on patents during this period can be viewed at: <https://www.suven.com/Patentupdates.aspx>.

We request you to take these documents on your records.

The Board Meeting commenced at 11:30 AM IST and concluded at 12:40 PM IST.

Thanking you.  
Yours faithfully,  
For **Suven Life Sciences Limited**

**Shrenik Soni**  
Company Secretary & Compliance Officer

Encl.: as above

## **Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com



## Suven Life Sciences Limited

Registered Office: 8-2-334, SDE Serene Chambers, 6th Floor, Road No. 5, Avenue 7, Banjara Hills, Hyderabad, Telangana, India 500034  
CIN: L24110TG1989PLC009713 Tel: +91 40 2354 1142/ 1152 email: investorservices@suven.com website: www.suven.com

### STATEMENT OF UN-AUDITED STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER & NINE MONTHS ENDED DECEMBER 31, 2025

Rs. In Lakhs

Sl. No.	PARTICULARS	STANDALONE					
		For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
<b>1</b>	<b>Income</b>						
	Revenue from operations	280.87	91.92	160.99	559.46	518.88	665.58
	Other Income	276.59	377.78	156.93	713.27	953.51	1,072.59
	<b>Total income</b>	<b>557.46</b>	<b>469.70</b>	<b>317.92</b>	<b>1,272.73</b>	<b>1,472.39</b>	<b>1,738.17</b>
<b>2</b>	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	626.84	607.65	486.58	1,832.05	1,475.88	2,082.49
	d) Finance costs	-	-	0.79	-	4.66	4.66
	e) Depreciation and amortisation expense	134.58	131.68	153.35	403.10	447.50	582.17
	f) R & D Expenses	590.96	877.32	826.49	1,987.05	2,194.43	3,043.16
	g) Other Expenses	552.25	397.56	177.90	1,420.08	550.89	733.67
	<b>Total expenses</b>	<b>1,904.63</b>	<b>2,014.21</b>	<b>1,645.11</b>	<b>5,642.28</b>	<b>4,673.36</b>	<b>6,446.15</b>
<b>3</b>	<b>Profit before exceptional items &amp; Tax (1-2)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>4</b>	Exceptional Items	-	-	-	-	-	-
<b>5</b>	<b>Profit before Tax (3-4)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>6</b>	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	-
<b>7</b>	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(1,347.17)</b>	<b>(1,544.51)</b>	<b>(1,327.19)</b>	<b>(4,369.55)</b>	<b>(3,200.97)</b>	<b>(4,707.98)</b>
<b>8</b>	<b>Other Comprehensive Income</b>						
<b>8.a</b>	(i) Items that will not be reclassified to profit or loss	3.26	(1.50)	(0.45)	0.26	(1.35)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
<b>8.b</b>	(i) Items that will be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>3.26</b>	<b>(1.50)</b>	<b>(0.45)</b>	<b>0.26</b>	<b>(1.35)</b>	<b>(5.99)</b>
<b>9</b>	<b>Total Comprehensive Income for the period (7+8)</b>	<b>(1,343.91)</b>	<b>(1,546.01)</b>	<b>(1,327.64)</b>	<b>(4,369.29)</b>	<b>(3,202.32)</b>	<b>(4,713.97)</b>
<b>10</b>	Paid-up equity share capital	2,274.74	2,274.74	2,180.74	2,274.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
<b>11</b>	Other Equity						77,770.36
<b>12</b>	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>						
	a) Basic	(0.60)	(0.70)	(0.61)	(1.95)	(1.47)	(2.16)
	b) Diluted	(0.60)	(0.70)	(0.61)	(1.95)	(1.47)	(2.16)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



*U. S. J. S.*

		CONSOLIDATED					
Sl. No.	PARTICULARS	For the Quarter Ended			For the Nine Months period ended		For the year ended
		31/12/2025	30/09/2025	31/12/2024	31/12/2025	31/12/2024	31/03/2025
		UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	UN AUDITED	AUDITED
1	<b>Income</b>						
	Revenue from operations	280.87	91.92	160.99	559.46	518.88	665.58
	Other Income	277.45	377.80	163.05	715.23	967.44	1,089.69
	<b>Total income</b>	<b>558.32</b>	<b>469.72</b>	<b>324.04</b>	<b>1,274.69</b>	<b>1,486.32</b>	<b>1,755.27</b>
2	<b>Expenses</b>						
	a) Cost of materials consumed	-	-	-	-	-	-
	b) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
	c) Employee benefits expense	626.84	607.65	486.58	1,832.05	1,475.88	2,082.49
	d) Finance costs	-	-	0.79	-	4.66	4.66
	e) Depreciation and amortisation expense	134.58	131.68	153.35	403.10	447.50	582.17
	f) R & D Expenses	9,404.72	7,032.13	3,413.32	20,585.69	10,663.68	14,396.18
	g) Other Expenses	584.36	429.25	181.66	1,528.71	574.61	764.27
	<b>Total expenses</b>	<b>10,750.50</b>	<b>8,200.71</b>	<b>4,235.70</b>	<b>24,349.55</b>	<b>13,166.33</b>	<b>17,829.77</b>
3	<b>Profit before exceptional items, Tax (1-2)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
4	Exceptional Items	-	-	-	-	-	-
5	<b>Profit before Tax (3-4)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
6	Tax Expenses						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
	c) Tax of earlier years	-	-	-	-	-	-
7	<b>Net Profit/ (Loss) for the period/year(5-6)</b>	<b>(10,192.18)</b>	<b>(7,730.99)</b>	<b>(3,911.66)</b>	<b>(23,074.86)</b>	<b>(11,680.01)</b>	<b>(16,074.50)</b>
8	<b>Other Comprehensive Income</b>						
8.a	(i) Items that will not be reclassified to profit or loss	3.26	(1.50)	(0.45)	0.26	(1.35)	(5.99)
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
8.b	(i) Items that will be reclassified to profit or loss	(78.39)	10.02	-	(71.99)	-	(52.34)
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	<b>Total other Comprehensive Income</b>	<b>(75.13)</b>	<b>8.52</b>	<b>(0.45)</b>	<b>(71.73)</b>	<b>(1.35)</b>	<b>(58.33)</b>
9	<b>Total Comprehensive Income for the period (7+ 8)</b>	<b>(10,267.31)</b>	<b>(7,722.47)</b>	<b>(3,912.11)</b>	<b>(23,146.59)</b>	<b>(11,681.36)</b>	<b>(16,132.83)</b>
10	Paid-up equity share capital	2,274.74	2,274.74	2,180.74	2,274.74	2,180.74	2,180.74
	Face Value of the Share	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00	Re.1.00
11	Other Equity	-	-	-	-	-	8,817.94
12	<b>Earning Per Share (EPS) (Face value of Rs.1/- each) :</b>						
	a) Basic	(4.55)	(3.48)	(1.79)	(10.31)	(5.36)	(7.37)
	b) Diluted	(4.55)	(3.48)	(1.79)	(10.31)	(5.36)	(7.37)
		(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)



**NOTES:-**

- 1) The above financial results of the Company has been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on January 29, 2026. The results for the quarter ended December 31, 2025 has been reviewed by our statutory auditors.
- 2) The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
- 3) The consolidated financial results include the results of the Wholly Owned Subsidiary, Suven Neurosciences, Inc.
- 4) The Company has only one business segment, i.e. Research & Development and does not operate in any other segments. Hence, segment reporting as per IND AS 108 (Operating Segment) is not presented.
- 5) ESOP: for the quarter ended December 31, 2025, the Company recognized an employee benefit expense (EBP) of Rs. 25.71 lakhs in accordance with Ind AS 102 – Share-based Payment. The cumulative EBP recognized as of December 2025 amounts to Rs.79.44 lakhs.

During the II quarter, out of 2,21,800 options under the 1st tranche, 2,14,000 options were exercised, and the Company received ₹117.70 lakhs pursuant to the exercise of employee stock options under its ESOP scheme. As of the reporting date, the equity shares corresponding to these exercised options had been allotted on 24.07.2025. The remaining unexercised options under the 1st tranche continue to be available for exercise by eligible employees, as the vesting period extends until 06-May-2027.

- 6) Preferential Issue: The Board of Directors of the Company approved the issue of 6,40,02,999 convertible warrants on a preferential basis to 23 allottees in its meeting held on 13th May, 2025, in accordance with the provisions of the Companies Act, 2013 and the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. Subsequently, shareholders of the Company approved the issue of convertible warrants in their meeting held on 05th June, 2025.

Each warrant is convertible into one equity share of face value ₹1/- at an exercise price of ₹134/- per share, within a period of 18 months from the date of allotment.

Out of the Issue proceeds of Rs.85,764 Lakhs, Rs.58,219 Lakhs has been received and Rs. 27,545 Lakhs is yet to be received from warrant holders. During the II quarter the Company has allotted 9186490 equity shares on a preferential basis upon conversion of equivalent number of fully paid warrants (allotted on 16.07.2025) to three allottees, upon receipt of 100% of the warrant consideration amounting to Rs.12,309.90 lakhs.

Summary of Utilisation of Proceeds of Preferential issue as on 31.12.2025

Particulars	Amount Rs.In lakhs
Amount Received through Preferential Issue	58,218.72
Less: Amount Utilised	18,062.24
<b>Balance Amount</b>	<b>40,156.48</b>

- 7) The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four Labour Code viz Code on wages 2019, Code on Social Security 2020, Industrial Relation Code 2020, and Occupational Safety, Health and Working Condition Code 2020 (collectively referred to as the New Labour Codes). These Codes have been made effective from November 21, 2025. The corresponding supporting rules under these codes are yet to be notified. The Company is in the process of evaluating the full impact of these new labour codes.

The Company has recognised and accounted for incremental liability for employee benefit expenses of Rs.36.34 Lakhs with respect to gratuity which is not material to the financial results. The Company continues to monitor the finalisation of Central/ State Rules and clarifications from the Government on other aspects of the New Labour Code.

- 8) The corresponding previous period figures have been regrouped / reclassified where ever necessary.



For SUVEN LIFE SCIENCES LIMITED

*Venkata Jasti*

**VENKAT JASTI**  
Chairman & MD  
DIN: 00278028

Place: Hyderabad  
Date : January 29, 2026

**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
UNAUDITED STANDALONE FINANCIAL RESULTS**

To  
**The Board of Directors of  
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **SUVEN LIFE SCIENCES LIMITED** for the quarter and nine months ended December 31, 2025 attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (the Regulation) as amended.
2. This statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ("Ind AS") specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For KARVY & CO**

Chartered Accountants  
(Firm Registration No.001757S)



**AJAYKUMAR KOSARAJU**

Partner  
M.No. 021989  
UDIN: 26021989GCMUCW7178

Place: Hyderabad  
Date : 29/01/2026



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM  
UNAUDITED CONSOLIDATED FINANCIAL RESULTS**

To  
**The Board of Directors of  
SUVEN LIFE SCIENCES LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial results of **SUVEN LIFE SCIENCES LIMITED** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and nine months ended December 31, 2025 (the "Statement") attached herewith, being submitted by the Parent pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended ('the Regulation')

2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting' prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India read with the Circular. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the Results of the following Entities:

<b>Name of the Company</b>	<b>Relationship</b>
Suven Life Sciences Limited	Parent
Suven Neuro Sciences Inc	Wholly Owned Subsidiary



29/01/2026

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standard specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatement.

6. We did not review the interim financial information of the subsidiary included in the unaudited consolidated financial results, whose interim financial information reflects total revenues of Rs. -Nil-, and Rs. -Nil- for the quarter ended and nine months period ended December 31, 2025 and total net loss after tax of Rs.(8,845.01) lakhs and Rs.(18,705.31) Lakhs for the quarter ended and nine months period ended December 31, 2025, and total comprehensive income of Rs.(8,923.40) Lakhs and Rs.(18,777.30) Lakhs for the quarter ended and nine months period December 31, 2025 as considered in the Statement. This interim financial information has been reviewed by another auditor whose report has been furnished to us by the Management, and our conclusion on the Statement, insofar as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditor.

Our conclusion on the statement is not modified in respect of the above matters.

**For KARVY & CO.,**  
Chartered Accountants  
(Firm Registration No .001757S)



**AJAYKUMAR KOSARAJU**  
Partner  
M.No.021989  
UDIN:26021989YABYXS4255



Place: Hyderabad  
Date : 29/01/2026

29/01/2026

## News Release

**HYDERABAD, INDIA (29 Jan 2026)** - Suven Life Sciences Limited ("Suven") today announced unaudited financial results for the quarter and nine months ended 31 Dec 2025. The unaudited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 29 Jan 2026 at Hyderabad.

### CONSOLIDATED STATEMENT OF OPERATIONS

INR Million, except EPS

	Quarter ended			Period ended		Year ended
	31-Dec-25	30-Sep-25	31-Dec-24	31-Dec-25	31-Dec-24	31-Mar-25
Revenue	55.83	46.97	32.40	127.47	148.63	175.53
R&D and Operational expenses	1,061.59	806.90	408.16	2,394.65	1,271.42	1,724.29
Depreciation and Amortisation	13.46	13.17	15.34	40.31	44.75	58.22
Finance cost	-	-	0.08	-	0.47	0.47
<b>Total expenses</b>	<b>1,075.05</b>	<b>820.07</b>	<b>423.57</b>	<b>2,434.96</b>	<b>1,316.63</b>	<b>1,782.98</b>
Exceptional items (insurance claim received)	-	-	-	-	-	-
Tax	-	-	-	-	-	-
<b>Profit/(Loss) After Tax for the period/year</b>	<b>(1,019.22)</b>	<b>(773.10)</b>	<b>(391.17)</b>	<b>(2,307.49)</b>	<b>(1,168.00)</b>	<b>(1,607.45)</b>
Other comprehensive income	(7.51)	0.85	(0.05)	(7.17)	(0.14)	(5.83)
<b>Total comprehensive income</b>	<b>(1,026.73)</b>	<b>(772.25)</b>	<b>(391.21)</b>	<b>(2,314.66)</b>	<b>(1,168.14)</b>	<b>(1,613.28)</b>
Paid up equity capital	227.47	227.47	218.07	227.47	218.07	218.07
<b>Earnings per share of Rs.1 each (EPS)</b>	<b>(4.55)</b>	<b>(3.48)</b>	<b>(1.79)</b>	<b>(10.31)</b>	<b>(5.36)</b>	<b>(7.37)</b>

(a) Suven, a Biopharmaceutical company, engaged in Drug Discovery and Development of New Chemical Entities (NCEs) in Central Nervous System (CNS) disorders targeting unmet medical needs, globally.

(b) The statement of operations includes financial of Suven Neurosciences, Inc., a Delaware Company, wholly owned subsidiary (WOS) of Suven, involved in clinical development programs of the Company.

(c) Clinical development pipeline:

- SUVN-502 (Masupirdine) – Ongoing phase 3 study for Agitation and Aggression in Alzheimer's type dementias in North America and Europe; Enrolling patients in sites in US and Europe. Expected completion of enrollment by end of calendar 2026.
- SUVN-G3031 (Samelisant) – Preparing to start Phase 3 clinical study for treatment of EDS in Narcolepsy by March/April 2026.
- SUVN-911 (Ropanicant) – Ongoing Phase 2B clinical study in USA is expected to be completed by July 2026.
- SUVN-D4010 (Usmarapride) – New IND submission done with FDA for Phase-2 POC (proof of concept) for the "Treatment of cognitive dysfunction in adults with major depressive disorder (MDD) and Phase 2 double blind study will start during calendar 2026.
- SUVN-I6107 – Ongoing Phase 1 study for establishing safety and pharmacokinetics will be completed by April 2026.

(d) Suven continues its R&D programs focused on Central Nervous System (CNS) disease disorders and granted 6 patents during the period covering countries Canada, EPOA, Mexico, Singapore, Sri Lanka and Thailand.

[For more information on Suven please visit our Web site at http://www.suven.com](http://www.suven.com)

#### **Risk Statement:**

Except for historical information, all the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking that involve number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including research and clinical development outcome, outsourcing trends, economic conditions, dependence on collaborative programs, retention of key personnel, technological advances and continued success in growth of revenue that may make our products/services offerings less competitive.

## Suven Life Sciences Limited

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

**Annexure A**
**Disclosure of information pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. no.	particulars	details								
a)	type of securities proposed to be issued (viz. equity shares, convertibles etc.);	Fully paid-up equity shares upon conversion of warrants								
b)	type of issuance (further public offering, rights issue, depository receipts (ADR/ GDR), qualified institutions placement, preferential allotment etc.);	Preferential Allotment in accordance with Chapter V of the SEBI ICDR Regulations and other applicable law.								
c)	total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately);	44,77,612 Equity Shares of face value of Rs. 1/- each pursuant to conversion of 44,77,612 warrants at an issue price of ₹ 134/- per warrant, for an aggregate consideration of Rs. 60,00,00,008/- to below allottees.								
d)	in case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):									
	i. number of investors;	2								
	ii. names of the investors;	<table border="1"> <thead> <tr> <th>Particulars</th> <th>No. of Equity Shares allotted</th> </tr> </thead> <tbody> <tr> <td colspan="2"><b>Non-promoter persons/entities</b></td> </tr> <tr> <td>3P INDIA EQUITY FUND 1</td> <td>33,58,209</td> </tr> <tr> <td>3P INDIA EQUITY FUND 1M</td> <td>11,19,403</td> </tr> </tbody> </table>	Particulars	No. of Equity Shares allotted	<b>Non-promoter persons/entities</b>		3P INDIA EQUITY FUND 1	33,58,209	3P INDIA EQUITY FUND 1M	11,19,403
Particulars	No. of Equity Shares allotted									
<b>Non-promoter persons/entities</b>										
3P INDIA EQUITY FUND 1	33,58,209									
3P INDIA EQUITY FUND 1M	11,19,403									
	iii. post allotment of securities - outcome of the subscription	Pursuant to conversion, the issued, subscribed and paid-up equity share capital of the Company stands increased to Rs. 23,19,51,819/- consisting of 23,19,51,819 fully paid-up equity shares of Rs. 1/- each.								
	iv. issue price/ allotted price (in case of convertibles)	Rs. 134/- per share								
	v. in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Allotment of 44,77,612 equity shares pursuant to the conversion of warrants at an issue price of Rs. 134/- each (face value of Rs. 1/- each and premium of Rs. 133/- each) upon receipt of 100% consideration amount from above mentioned allottees amounting to Rs. 60,00,00,008/-.								
e)	any cancellation or termination of proposal for issuance of securities including reasons thereof.	Not applicable								

**Suven Life Sciences Limited**

**Annexure B**
**Disclosure of information pursuant Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. No	Particulars	Details
1)	Reason for change viz. <del>appointment, re-appointment, cessation, removal, death or otherwise</del> resignation,	Mr. Shrenik Soni (ICSI Membership No.: F12400) has tendered his resignation from the position of Company Secretary & Compliance Officer (Key Managerial Personnel) of the Company vide resignation letter dated 11 <sup>th</sup> November, 2025, to pursue alternate career opportunity and there was no other material reason.
2)	Date of <del>appointment/</del> cessation (as applicable) & <del>term of appointment</del>	Mr. Shrenik Soni will cease to be Key Managerial Personnel of the Company, with effect from close of business hours on January 30, 2026.
3)	Brief profile (in case of appointment)	Not Applicable
4)	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

**Suven Life Sciences Limited**

Registered Office: 8-2-334 | SDE Serene Chambers | 6th Floor Road No.5 | Avenue 7  
 Banjara Hills | Hyderabad – 500034 | Telangana | India | CIN: L24110TG1989PLC009713  
 Tel: 91 40 2354 1142/ 1152 Email: info@suven.com website: www.suven.com

## Resignation Letter

Date: 11/11/2025

To

**The Board of Directors**  
**Suven Life Sciences Limited,**  
6th Floor, SDE Serene Chambers,  
Road No 5, Banjara Hills,  
Hyderabad – 500 034

Dear Sir/Madam,

**Subject: Resignation from the position of Company Secretary and Compliance Officer of the Company**

With reference to the above-mentioned subject, I hereby tender my resignation as Company Secretary and Compliance Officer (KMP) and all other statutory/ designated positions in the Company, to pursue an alternate career opportunity and confirm that there is no other material reason.

I request you to relieve me of duties and responsibilities effective from close of business hours on January 30, 2026.

I hereby convey my sincere thanks to the Board of Directors and Management of the Company for their unstinted support and cooperation extended during my tenure as Company Secretary and Compliance Officer of the Company.

Thanking You,  
Yours Sincerely,



**Shrenik Soni**  
(ICSI Membership No.: F12400)

Received & approved  
30 Jan 2026  
WA 28

**Annexure C**
**Disclosure of information pursuant Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Sl. No	Particulars	Details
1)	Reason for change viz. appointment, resignation, removal, death or otherwise	Appointment of Ms. Sangeetha Laxmi Kandari (ICSI Membership No: A40736) as Company Secretary & Compliance Officer of the Company.
2)	Date of appointment/ reappointment/ cessation (as applicable)	Appointment of Ms. Sangeetha Laxmi Kandari as 'Company Secretary and Compliance Officer'. She would take over as Company Secretary and Compliance Officer (Key Managerial Personnel) of the Company with effect from February 02, 2026.
3)	term of appointment	Not Applicable
4)	Brief profile (in case of appointment)	Ms. Sangeetha Laxmi (ICSI Membership No: A40736), is a qualified Company Secretary and a member of the Institute of Company Secretaries of India (ICSI) with Post-Graduation in Commerce. She is a seasoned corporate governance professional with more than 9 years of experience in Corporate, Secretarial, and Compliance function. Prior to joining Suven, she was associated with Shilpa Biocare Pvt. Ltd, Avra Laboratories Pvt. Ltd and Prasad Media Corporation Pvt. Ltd.
5)	Disclosure of relationships between directors (in case of appointment of a director)	Not Applicable

**Suven Life Sciences Limited**